Does extended-duration betrixaban improve outcomes compared to a standard regimen of enoxaparin in acutely ill medical patients with an elevated d-dimer level?
Extended-duration betrixaban did not significantly improve the primary efficacy outcome compared to standard enoxaparin in acutely ill medical patients with elevated d-dimer, though exploratory analyses suggested potential benefit.
Among acutely ill medical patients with an elevated d-dimer level, there was no significant difference between extended-duration betrixaban and a standard regimen of enoxaparin in the prespecified primary efficacy outcome. However, prespecified exploratory analyses provided evidence suggesting a benefit for betrixaban in the two larger cohorts. (Funded by Portola Pharmaceuticals; APEX ClinicalTrials.gov number, NCT01583218.).
Cohen et al. (Fri,) studied this question.